US$ 27.69
glp 1 agonists for type 2 diabetes The activity of GLP-1 and GIP and Obesity Practice Nursing - GLP-1 receptor
Description
10.2337/db07-0100 27

The DPP-4 inhibitors offer the advantage of no weight gain

Several drugs are in advanced clinical trials: In Phase III trials: IBI362 (Innovent/Eli Lilly), CagriSema (Novo Nordisk), Retatrutide (Eli Lilly), and Survodutide (Boehringer Ingelheim)

PLoS One 13 , e0196625 (2018)

518 This was observed through improved glycemic control, reduced occurrence of liver cancer, and better liver histology compared to the control group

all patients should titrate to 1.2 mg after the first week to receive therapeutic levels for maximum antiglycemic effect (14)
